Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03600428 · ClinicalTrials.gov registry record · Phase 4
Safety of LAIV4 in Children With Asthma
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 152
- Enrollment target
NCT03600428 is a Phase 4 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 152 participants.
The verdict
NCT03600428, a Phase 4 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 152 participants
- Enrollment target
Study Summary
This is a prospective randomized, open label clinical trial in approximately 300 children aged 5-11 years with a physician diagnosis of persistent asthma. Participants will be randomized 1:1 to receive either a single intranasal dose of licensed quadrivalent LAIV (LAIV4) or an intramuscular injection of quadrivalent IIV4 (IIV4).
Interventions
- BIOLOGICAL Live Attenuated Influenza Vaccine (LAIV)
- BIOLOGICAL Inactivated Influenza Vaccine (IIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2020-03-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03600428
The ClinicalTrials.gov registry entry for NCT03600428 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Live Attenuated Influenza Vaccine (LAIV) is the first listed.
NCT03600428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03600428 about?
NCT03600428 is a clinical study titled "Safety of LAIV4 in Children With Asthma". This is a prospective randomized, open label clinical trial in approximately 300 children aged 5-11 years with a physician diagnosis of persistent asthma. Participants will be randomized 1:1 to receive either a single intranasal dose of licensed quadrivalent LAIV (LAIV4) or an intramuscular injectio...
What is the current status of trial NCT03600428?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 152 participants. The study started on 2018-10-15. Estimated completion is 2020-03-20.
What interventions are being tested in trial NCT03600428?
The interventions under investigation include: Live Attenuated Influenza Vaccine (LAIV) (BIOLOGICAL), Inactivated Influenza Vaccine (IIV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03600428?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.